111 related articles for article (PubMed ID: 12461034)
1. Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Drago L; De Vecchi E; Lombardi A; Nicola L; Valli M; Gismondo MR
J Antimicrob Chemother; 2002 Dec; 50(6):1059-63. PubMed ID: 12461034
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Esel D; Doganay M; Sumerkan B
Int J Antimicrob Agents; 2003 Jul; 22(1):70-2. PubMed ID: 12842331
[TBL] [Abstract][Full Text] [Related]
3. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
Kays MB; Lisek CR; Denys GA
Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
Nicolau DP; Ambrose PG
Am J Med; 2001 Dec; 111 Suppl 9A():13S-18S; discussion 36S-38S. PubMed ID: 11755438
[TBL] [Abstract][Full Text] [Related]
7. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.
Cottagnoud P; Cottagnoud M; Acosta F; Flatz L; Kühn F; Stucki A; Entenza J
Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):656-62. PubMed ID: 14557920
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory and bactericidal activity of rokitamycin against Helicobacter pylori and morphological alterations.
Brenciaglia MI; Fornara AM; Scaltrito MM; Braga PC
J Chemother; 1996 Dec; 8(6):425-31. PubMed ID: 8981182
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Frei CR; Burgess DS
Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
[TBL] [Abstract][Full Text] [Related]
10. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Ebisu H; Kishii R; Takei M; Fukuda H
J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
[TBL] [Abstract][Full Text] [Related]
11. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
Ambrose PG; Grasela DM
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):151-7. PubMed ID: 11109013
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity.
Athamna A; Massalha M; Athamna M; Nura A; Medlej B; Ofek I; Bast D; Rubinstein E
J Antimicrob Chemother; 2004 Feb; 53(2):247-51. PubMed ID: 14688054
[TBL] [Abstract][Full Text] [Related]
14. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Louie A; VanScoy BD; Brown DL; Kulawy RW; Heine HS; Drusano GL
Antimicrob Agents Chemother; 2012 Mar; 56(3):1229-39. PubMed ID: 22155821
[TBL] [Abstract][Full Text] [Related]
15. [Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC, MBC, Time-Kill curves and bactericidal index analysis].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2002 Jun; 10(2):100-6. PubMed ID: 12702887
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
Garrison MW
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
[TBL] [Abstract][Full Text] [Related]
17. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
[TBL] [Abstract][Full Text] [Related]
18. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.
Cohn ML; Waites KB
Antimicrob Agents Chemother; 2001 Jul; 45(7):2126-8. PubMed ID: 11408235
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
Dawis MA; Isenberg HD; France KA; Jenkins SG
J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
